ERBB2 and breast cancer: After vaccination, anti-HER-2 CD4 immune response was detected in blood and sentinel lymph nodes of breast cancer patients, and patients with DCIS exhibited much higher rate of pathologic complete response (pCR) than IBC patients (28.6% vs. 8.3%).